Pharma
Gland Pharma Ltd
GLAND · NSE · INE068V01023Thursday, 10 Sept 202611:31 am
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE10.5%
ROCE13.5%
ROE10.5%
1Y Return+74.52%
Avg. Volume0.7M
Price Chart
52-Week Range
About
Gland Pharma Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹2,972.5
52W High / Low₹3,042 / ₹1,573.6
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE10.5%
1Y Return+74.52%
Day Change-1.73%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|---|
| Sales | ₹6,725 Cr | ₹6,431 Cr | ₹5,616 Cr | |||||
| Expenses | ₹4,974 Cr | ₹4,801 Cr | ₹4,348 Cr | |||||
| Operating Profit | ₹1,751 Cr | ₹1,630 Cr | ₹1,269 Cr | |||||
| OPM % | 26.0% | 25.0% | 23.0% | |||||
| Other Income | ₹296 Cr | ₹292 Cr | ₹214 Cr | |||||
| Depreciation | ₹434 Cr | ₹424 Cr | ₹378 Cr | |||||
| Interest | ₹26 Cr | ₹33 Cr | ₹42 Cr | |||||
| Profit Before Tax | ₹1,587 Cr | ₹1,465 Cr | ₹1,063 Cr | |||||
| Tax | ₹458 Cr | ₹438 Cr | ₹364 Cr | |||||
| Net Profit | ₹1,129 Cr | ₹1,027 Cr | ₹699 Cr | |||||
| EPS (₹) | 68.5 | 62.4 | 42.4 | |||||
| Dividend Payout % | — | 32% | 42% |
Financial history locked
Register freeRegister free to see 5 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,800 Cr | ₹1,743 Cr | ₹1,695 Cr | ₹1,487 Cr | |||||||||
| Expenses | ₹1,311 Cr | ₹1,230 Cr | ₹1,260 Cr | ₹1,173 Cr | |||||||||
| Operating Profit | ₹489 Cr | ₹513 Cr | ₹435 Cr | ₹314 Cr | |||||||||
| OPM % | 27.0% | 29.0% | 26.0% | 21.0% | |||||||||
| Depreciation | ₹111 Cr | ₹109 Cr | ₹108 Cr | ₹106 Cr | |||||||||
| Interest | ₹4 Cr | ₹10 Cr | ₹4 Cr | ₹8 Cr | |||||||||
| Net Profit | ₹317 Cr | ₹367 Cr | ₹261 Cr | ₹184 Cr | |||||||||
| EPS (₹) | 19.2 | 22.3 | 15.9 | 11.2 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹10,341 Cr | ₹9,134 Cr | ₹8,707 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹284 Cr | ₹314 Cr | ₹372 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,808 Cr | ₹1,709 Cr | ₹1,516 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹12,449 Cr | ₹11,173 Cr | ₹10,611 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹4,492 Cr | ₹4,147 Cr | ₹3,947 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹7,614 Cr | ₹6,875 Cr | ₹6,426 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹12,449 Cr | ₹11,173 Cr | ₹10,611 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 5 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,031 Cr | ₹188 Cr | ₹-417 Cr | ₹803 Cr |
| FY25 | ₹915 Cr | ₹1,718 Cr | ₹-433 Cr | ₹2,199 Cr |
| FY24 | ₹997 Cr | ₹-1,749 Cr | ₹-799 Cr | ₹-1,552 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 |
Cash flow history locked
Register freeRegister free to see 5 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-10Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE Filing2026-08-12Gland Pharma Ltd (NSE:GLAND) (Q1 2027) Earnings Call Highlights: Record 20% Revenue Growth and ...GuruFocus.com2026-08-07Earnings To Watch: Gland Pharma Ltd (NSE:GLAND) Q1 2027 -- GF Value Sees 5% DownsideGuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.